January 10, 2026

@michaelokun

Can we vaccinate against Parkinson’s disease? A vaccine based approach refers to training the immune system to recognize and target harmful proteins linked to disease before they cause damage. Ma, Tamgüney and colleagues describe in a new paper in the journal Brain, a vaccine based strategy designed to generate immunity against toxic alpha synuclein aggregates that may contribute to Parkinson’s disease. Key Points: - Engineered vaccines were designed to mimic the shape of toxic alpha synuclein fibrils, rather than the normal protein. - In mouse models, vaccination delayed disease onset, improved motor function and extended survival by up to about 40 percent. - Antibodies generated by the vaccine recognized pathological alpha synuclein found in brain tissue from Parkinson’s and related disorders. My take: This is a creative approach. Targeting the structure of misfolded alpha synuclein rather than the normal protein may help to avoid immune misfires. The approach is still early and limited to animal models. My biggest concern is whether targeting synuclein will be far enough upstream to make a big enough difference; several experts pointed out in www.pdplan.org Here are 5 points that resonated w/ me: 1- This approach focuses on prevention and very early disease, rather than rescue after damage is done. 2- Vaccines are part of a larger group of approaches using the immune system as treatment paradigms. These may possibly slow disease progression rather than reverse most symptoms. 3- Targeting toxic protein shapes could be safer than targeting the normal protein. 4- Benefits varied by vaccine design and delivery route, highlighting how personalized strategies may matter. 5- Could a long term vision could include vaccinating high risk groups before symptoms ever appear? Is synuclein the best target? https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awag010/8418338 #michaelokun #fixelinstitute #parkinson #vaccine